^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

TCR² ANNOUNCES RECIST RESPONSE IN OVARIAN CANCER FROM ONGOING PHASE 1/2 TRIAL OF TC-210 IN TREATMENT REFRACTORY MESOTHELIN-EXPRESSING SOLID TUMORS

Published date:
12/13/2020
Excerpt:
TCR2 Therapeutics Inc. (Nasdaq: TCRR)...today announced positive interim data from the ongoing Phase 1 portion of the TC-210 ( gavocabtagene autoleucel or “gavo-cel”) Phase 1/2 clinical trial for mesothelin-expressing solid tumors...Ovarian cancer patient achieved confirmed RECIST partial response (PR)...Overall response rate (ORR) 50% in patients infused with TC-210...